Predicted Trait | |
Reported Trait | Prostate cancer |
Mapped Trait(s) | prostate carcinoma (EFO_0001663) |
Score Construction | |
PGS Name | PRS125_prostate |
Development Method | |
Name | PRSice-2 |
Parameters | p = 5E-8, r2 = 0.1 |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 125 |
Effect Weight Type | log(OR) |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000542 |
Citation (link to publication) | Kim ES et al. NPJ Precis Oncol (2023) |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST006085 Europe PMC: 29892016 |
140,254 individuals | European | NR |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
37,272 individuals | European | NR |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
2,251 individuals | African American or Afro-Caribbean | NR |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
3,226 individuals | East Asian | NR |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
3,629 individuals | Hispanic or Latin American | NR |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM020315 | PSS011329| European Ancestry| 115,207 individuals |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Reported Trait: Prostate cancer | HR: 1.78 [1.72, 1.85] | — | — | first 10 genetic principal components | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS011329 | — | — | 115,207 individuals, 100.0 % Male samples |
— | European (British) |
— | UKB | — |